Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease

被引：0
|
作者：
Volkmann, Elizabeth R. [1 ]
Roth, Michael [1 ]
Elashoff, Robert [2 ]
Clements, Philip J. [1 ]
Furst, Daniel E. [1 ]
Khanna, Dinesh [3 ]
Goldin, Jonathan [4 ]
Tashkin, Donald [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Biomath, Los Angeles, CA 90095 USA
[3] Univ Michigan, Med, Ann Arbor, MI 48109 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1076
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease
    Robert L. Mango
    Eric L. Matteson
    Cynthia S. Crowson
    Jay H. Ryu
    Ashima Makol
    Lung, 2018, 196 : 409 - 416
  • [22] Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease
    Kim, Grace Hyun J.
    Tashkin, Donald P.
    Lo, Pechin
    Brown, Matthew S.
    Volkmann, Elizabeth R.
    Gjertson, David W.
    Khanna, Dinesh
    Elashoff, Robert M.
    Tseng, Chi-Hong
    Roth, Michael D.
    Goldin, Jonathan G.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 (02) : 316 - 325
  • [23] Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis Interstitial Lung Disease
    Khanna, Dinesh
    Albera, Carlo
    Fischer, Aryeh
    Seibold, James R.
    Khalidi, Nader A.
    Raghu, Ganesh
    Chung, Lorinda
    Schiopu, Elena
    Chen, Dan
    Gorina, Eduard
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [24] Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial
    Acharya, Nupoor
    Sharma, Shefali Khanna
    Mishra, Debashish
    Dhooria, Sahajal
    Dhir, Varun
    Jain, Sanjay
    RHEUMATOLOGY INTERNATIONAL, 2020, 40 (05) : 703 - 710
  • [25] DEVELOPMENT OF A COMPOSITE OUTCOME MEASURE FOR SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
    Volkmann, E.
    Li, N.
    Tashkin, D.
    Furst, D.
    Elashoff, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S28 - S28
  • [26] Distinct Immune Cell Subsets in Systemic Sclerosis-related Interstitial Lung Disease
    Saligrama, Phan
    Wilfong, Erin
    Rizzi, Elise
    Crofford, Leslie
    Kendall, Peggy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2306 - 2307
  • [27] DEVELOPMENT OF A COMPOSITE OUTCOME MEASURE FOR SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
    Volkmann, E.
    Li, N.
    Tashkin, D.
    Furst, D.
    Elashoff, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 165 - 165
  • [28] Induced sputum as a method for detection of systemic sclerosis-related interstitial lung disease
    Neslihan Yilmaz
    Yasin Abul
    Muge Bicakcigil
    Pejman Golabi
    Cigdem Celikel
    Sait Karakurt
    Sule Yavuz
    Rheumatology International, 2012, 32 : 1921 - 1925
  • [29] Induced sputum as a method for detection of systemic sclerosis-related interstitial lung disease
    Yilmaz, Neslihan
    Abul, Yasin
    Bicakcigil, Muge
    Golabi, Pejman
    Celikel, Cigdem
    Karakurt, Sait
    Yavuz, Sule
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (07) : 1921 - 1925
  • [30] Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease
    Assassi, Shervin
    Volkmann, Elizabeth R.
    Zheng, W. Jim
    Wang, Xuan
    Wilhalme, Holly
    Lyons, Marka A.
    Roth, Michael D.
    Tashkin, Donald P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 854 - 860
12345